ImmunityBio Inc [NASDAQ: IBRX] price plunged by 0.00 percent to reach at $0.0.
A sum of 8582087 shares traded at recent session while its average daily volume was at 9.28M shares. ImmunityBio Inc shares reached a high of $3.0 and dropped to a low of $2.7 until finishing in the latest session at $2.72.
The one-year IBRX stock forecast points to a potential upside of 76.14. The average equity rating for IBRX stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on ImmunityBio Inc [IBRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBRX shares is $11.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBRX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for ImmunityBio Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 20, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 06, 2025, representing the official price target for ImmunityBio Inc stock. Previously, the target price had yet another raise to $6, while BTIG Research analysts kept a Buy rating on IBRX stock. On May 12, 2023, analysts decreased their price target for IBRX shares from 10 to 4.
IBRX Stock Performance Analysis:
ImmunityBio Inc [IBRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.74. With this latest performance, IBRX shares dropped by -7.17% in over the last four-week period, additionally plugging by 6.25% over the last 6 months – not to mention a rise of 6.25% in the past year of trading.
Insight into ImmunityBio Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and ImmunityBio Inc [IBRX] shares currently have an operating margin of -1003.83% and a Gross Margin at 45.92%. ImmunityBio Inc’s Net Margin is presently recorded at -1310.30%.
Return on Equity for this stock declined to -116.15%, with Return on Assets sitting at -116.15%.
ImmunityBio Inc [IBRX] Institutonal Ownership Details
There are presently around $9.24%, or 35.68% of IBRX stock, in the hands of institutional investors. The top three institutional holders of IBRX stocks are: VANGUARD GROUP INC with ownership of 13.83 million shares, which is approximately 2.0135%. BLACKROCK INC., holding 11.42 million shares of the stock with an approximate value of $$72.19 million in IBRX stocks shares; and BLACKROCK INC., currently with $$49.7 million in IBRX stock with ownership which is approximately 1.1448%.
